44 completed. 44 Phase 1, 11 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 44 | Completed 44 |
| Phase 2 | 11 | Completed 11 |
Follow Glomerulonephritis: new trials by email Literature Review of Glomerulonephritis trials Research Report on Glomerulonephritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study to Evaluate the Effect of Food on the Pharmacokinetic Profiles of HRS-5965 Capsules in Healthy Subjects HRS-5965 Capsules - IgA Nephropathy, Paroxysmal Nocturnal Hemoglobinuria | Phase 1 | Completed | Chengdu Suncadia Medicine Co., Ltd. | 16 | 2025-06-30 | 2025-08-20 |
| Phase IIa Study for IPG11406 in Patients With Lupus Nephritis IPG11406 - Lupus Nephritis | Phase 1 / Phase 2 | Completed | Nanjing Immunophage Biotech Co., Ltd | 24 | 2025-02-25 | 2026-09-09 |
| Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment IXP - Focal Segmental Glomerulosclerosis (FSGS) | Phase 1 | Completed | Vertex Pharmaceuticals Incorporated | 36 | 2024-08-02 | 2025-01-20 |
| Study of ARO-CFB in Adult Healthy Volunteers ARO-CFB, Placebo - IgA Nephropathy | Phase 1 | Completed | Arrowhead Pharmaceuticals | 49 | 2024-04-05 | 2026-05-20 |
| Relative Bioavailability Study of HR19042 in Healthy Subjects HR19042 Capsule, Tarpeyo®, Budenofalk® - Primary IgA Nephropathy; Autoimmune Hepatitis | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 18 | 2023-12-27 | 2025-04-22 |
| A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old Felzartamab - Lupus Nephritis | Phase 1 | Completed | HI-Bio, A Biogen Company | 14 | 2023-11-01 | 2026-07-17 |
| A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147 VX-147 - Focal Segmental Glomerulosclerosis (FSGS) | Phase 1 | Completed | Vertex Pharmaceuticals Incorporated | 21 | 2023-07-19 | 2023-09-13 |
| An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus YTB323 - Systemic Lupus Erythematosus, Lupus Nephritis | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 21 | 2023-02-28 | 2026-10-15 |
| Study of HRS-5965 in Healthy Subjects and Subjects With Renal Insufficiency HRS-5965, Placebo - Glomerulonephritis | Phase 1 | Completed | Chengdu Suncadia Medicine Co., Ltd. | 83 | 2022-10-08 | 2024-10-23 |
| A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy Mezagitamab - Kidney Disease, Glomerulonephritis | Phase 1 | Completed | Takeda | 17 | 2022-08-16 | 2026-06-01 |
| A Study of ANX009 in Adult Participants With Lupus Nephritis ANX009 - Lupus Nephritis | Phase 1 | Completed | Annexon, Inc. | 7 | 2022-08-09 | 2024-08-22 |
| A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Pharmacodynamics of SHR-2010 by Intravenously/Subcutaneously in Healthy Subject SHR-2010 injection, SHR-2010 injection placebo - IgA Nephropathy | Phase 1 | Completed | Guangdong Hengrui Pharmaceutical Co., Ltd | 61 | 2022-06-30 | 2023-03-23 |
| Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria ALXN1720 - Proteinuria | Phase 1 | Completed | Alexion Pharmaceuticals, Inc. | 13 | 2022-06-29 | 2023-06-29 |
| Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease ARO-C3, Placebo - C3 Glomerulopathy, IgA Nephropathy | Phase 1 / Phase 2 | Completed | Arrowhead Pharmaceuticals | 62 | 2022-02-01 | 2026-05-22 |
| A Trial of HR19042 Capsule in Healthy Chinese Subjects HR19042 capsule - Primary IgA Nephropathy | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 12 | 2021-07-01 | 2021-09-24 |
| A Prospective Multi-dose Study of Apixaban in Subjects With Nephrotic Syndrome Apixaban 5 MG - Nephrotic Syndrome, Membranous Nephropathy | Phase 1 | Completed | University of North Carolina, Chapel Hill | 22 | 2021-04-14 | 2023-09-26 |
| Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome Dalteparin, Apixaban - Nephrotic Syndrome, Thromboembolic Disease | Phase 1 / Phase 2 | Completed | University of Aarhus | 57 | 2021-03-25 | 2025-04-11 |
| Study to Evaluate the Pharmacokinetics of Oral Sparsentan Suspension RE-021, sparsentan - Healthy Subjects | Phase 1 | Completed | Travere Therapeutics, Inc. | 47 | 2020-06-18 | 2022-09-30 |
| The Clinical Trial of ADR-001 for IgA Nephropathy infusion of ADR-001 (Mesenchymal stem cell) - Glomerulonephritis , IGA | Phase 1 | Completed | Nagoya University | 9 | 2020-06-15 | 2023-05-01 |
| Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) MOR202 - Glomerulonephritis, Membranous, antiPLA2R Positive | Phase 1 / Phase 2 | Completed | HI-Bio, A Biogen Company | 31 | 2019-10-15 | 2025-02-24 |
Showing 20 of 44. Sign in to see all of them.
Lupus Nephritis (15) · Glomerulonephritis, IGA (12) · Glomerulosclerosis, Focal Segmental (10) · Lupus Erythematosus, Systemic (8) · Glomerulonephritis, Membranous (4) · Kidney Diseases (4) · Proteinuria (4) · Glomerulonephritis, Membranoproliferative (3) · Nephrotic Syndrome (3) · Diabetic Nephropathies (2) · Nephritis (2) · Renal Insufficiency, Chronic (2) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Atypical Hemolytic Uremic Syndrome (1)
Female Urogenital Diseases (44) · Female Urogenital Diseases and Pregnancy Complications (44) · Male Urogenital Diseases (44) · Urogenital Diseases (44) · Urologic Diseases (43) · Nephritis (42) · Kidney Diseases (40) · Immune System Diseases (32) · Autoimmune Diseases (30) · Skin and Connective Tissue Diseases (16) · Connective Tissue Diseases (15) · Lupus Erythematosus, Systemic (7) · Pathological Conditions, Signs and Symptoms (7) · Disease Attributes (4)
Cyclophosphamide (3) · Adrenocorticotropic Hormone (2) · apixaban (2) · felzartamab (2) · Abatacept (1) · Adalimumab (1) · Bone Marrow Purging (1) · Budesonide (1) · Celecoxib (1) · Dalteparin (1) · Immunoglobulin Fab Fragments (1) · Immunoglobulin G (1) · Itraconazole (1) · KZR-616 (1) · Midazolam (1)
Arrowhead Pharmaceuticals (2) · Chengdu Suncadia Medicine Co., Ltd. (2) · HI-Bio, A Biogen Company (2) · Jiangsu HengRui Medicine Co., Ltd. (2) · Mayo Clinic (2) · Novartis Pharmaceuticals (2) · Vertex Pharmaceuticals Incorporated (2) · Alexion Pharmaceuticals, Inc. (1) · Amgen (1) · Annexon, Inc. (1) · Biocon Limited (1) · Bristol-Myers Squibb (1) · Columbia University (1) · Corestemchemon, Inc. (1) · Genzyme, a Sanofi Company (1)
United States (21) · China (8) · Australia (6) · South Korea (6) · United Kingdom (5) · Germany (4) · Canada (3) · Italy (3) · Poland (3) · Spain (3) · Brazil (2) · France (2) · Japan (2) · New Zealand (2) · Taiwan (2)
Betty Diamond, MD (1) · Daniel Cattran, M.D (1) · Daniel Crona, PharmD, PhD (1) · David Wofsy, MD (1) · Debbie Gipson, MD (1) · Erling B Pedersen, Professor (1) · Esther Yoon, MD (1) · Fernando C Fervenza, M.D., Ph.D (1) · Gerald B Appel, MD (1) · Hanns-Martin Lorenz, Professor (1) · Howard Trachtman, MD (1)
PMID 34778952, PMID 38299639, PMID 40465397, PMID 15807196, PMID 21356124, PMID 22403278, PMID 35224732, PMID 35412950, PMID 35570983, PMID 35692547, PMID 37528520, PMID 39015674, PMID 39186380, PMID 39356039, PMID 40297949, PMID 40337980, PMID 40378845, PMID 40444214, PMID 40478760, PMID 40482854, PMID 40936477, PMID 41333097, PMID 41805697, PMID 42275148
2023 (2), 2018 (1)